



Critical Outcome

Technologies Inc.

The future of drug discovery has arrived

Reducing development time, cost & risk


Business Overview | October 2014

Critical Outcome Technologies Inc.



A biotechnology company focused on accelerating the discovery, optimization, & pre-clinical validation of small molecules

- TSX-V: COT
- OTC: COTQF



2

Disclaimer



When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI).

COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI's public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission.

All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation.

3

Investment highlights




- 1 Platform technology that reduces the time, cost & risk of bringing new drugs to market
- 2 Potential cancer breakthrough drug candidate – COTI-2
- 3 Many other revenue opportunities in our pipeline

4

We reduce risk & accelerate timeframes



Preclinical Development Steps



5

How we do it – CHEMSAS®

- Proprietary, machine learning (AI) based drug discovery platform technology
- Big Data analysis solutions



Advantages of CHEMSAS®


Database driven computational replication of traditional 'wet lab' drug discovery process

Costly failed attempts occur **quickly & cheaply** in computer simulations, not the 'wet lab'

Increased probability of clinical & commercial success

COTI-2: a promising advance


- Potential breakthrough treatment for many cancers
- Effective against many common cancers with a p53 gene mutation
- > 50% of all human cancers have a p53 mutation (eg. ~ 95% of serous ovarian cancers)



8

COTI-2: background

- 3rd generation Thiosemicarbazone



- A small molecule discovered by our CHEMSAS[®] process
- Engineered for low toxicity and easily synthesized in 3 steps
- Demonstrates strong *in vitro* and *in vivo* activity

COTI-2: first and best-in-class potential




- Novel p53-dependent mechanism of action confirmed by Dr. Gordon Mills at MD Anderson Cancer Center
- Orally bio-available and effective at low dose
- Low toxicity in preclinical development
- Opportunity for single agent and combination therapy
- Strong IP protection in place
 - 6 issued U.S. patents
 - 1 issued Japanese patent
 - 1 issued Canadian patent

10

COTI-2 and p53 protein levels



- COTI-2 significantly reduces p53 mutant protein levels and significantly increases wild-type p53 protein levels in TOV-112D cells likely by inducing a conformational change




Mutant p53 Levels in the presence/absence of COTI-2

• (*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control)

11

COTI-2 and p53 protein levels

- COTI-2 has no significant effect on p53 protein levels in the H460 cell line, which do not carry the mutant p53 protein




Wild-type p53 Levels in the Presence/Absence of COTI-2

- (*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control)

12

COTI-2 and Ovar-3 tumor volumes



Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control

13


Orphan Drug Designation

- Granted in June, 2014 by the FDA for the treatment of ovarian cancer
- Potentially qualifies us for:
 - Assistance in study design
 - Expedited drug development
 - Development grants & fee reductions
 - 7-year exclusive marketing period

14

MD Anderson experiments

- Independently confirmed COTI-2's novel p53 dependent MOA
- Confirmed COTI-2's selective & potent anti-cancer activity
- Identified effective dosage 60% lower than in prior animal experiments



15

MD Anderson LOI for Phase 1



- Very favourable cost structure
 - *COTI contribution ~ USD \$1.25 million*
 - *Remainder provided by MD Anderson*
- Dr. Mills and his team are very familiar with COTI-2's mechanism of action ("MOA")
- MD Anderson has the state-of-the-art facilities, technical capabilities & expertise to execute a high quality single site study

16

COTI-2: the pathway to the clinic



- Final pre-clinical toxicity studies required by the FDA completed
- FDA IND filing expected mid-November 2014
- Final agreements with MD Anderson for Phase 1 clinical development to be signed
- Phase 1 to begin early 2015
- Phase 1 completion mid-2016

17

U.S. ovarian indication – revenue potential



- ~ 190k patients - ~ 96% have a p53 mutation
 - If COTI-2 has meaningful affect on 50% of these ~ 91,200 patients
 - If drug cost to patient is \$10k per year = \$912M USD or CAD ~ \$1B
 - At a 10% annual royalty = \$100m
-
- Many other indications with p53 mutations are being explored including combination therapy

18

Other revenue opportunities



- Robust internal pipeline of drug candidates
 - AML, MRSA, colorectal and other cancers, MS, etc.
- 3 existing R&D collaborations expected to bring in milestone payments beginning late 2014 / 2015
 - Western University
 - Delmar Chemicals
 - Major Pharma Co.

19

CHEMFirm



- A small molecule profiling & investment due diligence tool leveraging the CHEMSAS® platform
- Provides detailed report on compound attributes and specific areas for further assessment
 - Identifies properties outside the optimal range that may represent development challenges

20

Benefits of CHEMFirm



- Enables institutions, investment banks, funds and biotechnology companies to make more knowledgeable investment decisions
- Provides critical information for assessing both risk and value
- Supports a lower risk and higher return investment strategy

21

Other future CHEMSAS® applications



- **Drug library profiling**
Based on customer identified criteria
- **Drug repurposing**
Finding new purposes for drugs coming off patent



Summary investment highlights



- 1 Platform technology that reduces the time, cost & risk of bringing new drugs to market
- 2 Potential cancer breakthrough drug candidate – COTI-2
- 3 Many other revenue opportunities in our pipeline



Critical Outcome

Technologies Inc.

The future of drug discovery has arrived

Reducing development time, cost & risk

Dr. Wayne Danter
President & CEO
Tel: (519) 858-5157
wdanter@criticaloutcome.com

www.criticaloutcome.com
www.facebook.com/criticaloutcome
twitter.com/criticaloutcome
www.slideshare.net/criticaloutcome

Appendix A: Key company facts



Trading	
TSX Venture	COT
Recent Closing Price ⁽¹⁾	\$0.25
52 Week Range ⁽¹⁾	\$0.12 - 0.365
Capital	
Cash ⁽²⁾	\$868,707
Basic Shares Outstanding ⁽¹⁾	103,748,240
Options Outstanding ⁽¹⁾	5,601,433
Warrants Outstanding ⁽¹⁾	57,614,571
Fully Diluted Shares Outstanding ⁽¹⁾	166,964,244
Contingent Rights Outstanding ⁽³⁾	715,720
Board & management control ⁽¹⁾	15.98%

(1) As at September 30, 2014

(2) Cash = cash and cash equivalents at July 31, 2014

(3) Contingent rights not included in fully diluted under IFRS

25

Appendix B: Committed leadership



Management Team

Wayne Danter, MD, FRCPC

- President, CEO & CSO
- Former Associate Professor of Medicine at the University of Western Ontario
- Co-founder of COTI

Gene Kelly

- Chief Financial Officer
- Former VP Finance, Cuddy Farms
- Former VP Commodities & Industry Relations, Cuddy Foods
- Former VP Strategic Implementations, Cuddy Farms

Directors

John Drake, LLB

- President and Founding Shareholder Drake Goodwin Corporation

Wayne Danter, MD, FRCPC

Douglas Alexander, CA

- Professional Director
- Chairman - Hydrogenics Corporation

Bruno Maruzzo, MSc, MBA

- President, TechnoVenture Inc.
- Professional Director

Dave Sanderson, LLB

- President & CEO of KFL Investment Management Inc.

26